Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: Reargument of such contentious therapeutic preferences

Clinical and Translational Oncology

Volumn 15, Issue 10, 2013, Pages 780-788

  Ren, Jun ^a,b   Di, Lijun ^a   Song, Guohong ^a   Yu, Jing ^a   Jia, Jun ^a   Zhu, Yuling ^a   Yan, Ying ^a   Jiang, Hanfang ^a   Liang, Xu ^a   Che, Li ^a   Zhang, Jie ^a   Wan, Fengling ^a   Wang, Xiaoli ^a   Zhou, Xinna ^a   Lyerly, Herbert Kim ^a,c  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokine induced killers; Dendritic cells; High dose chemotherapy; Immunotherapy; Metastatic breast cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; THIOTEPA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD34 SELECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEURITIS; NEUTROPENIA; OVERALL SURVIVAL; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TAXOIDS; THIOTEPA;

EID: 84885187708     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1001-9     Document Type: Article

References (20)

1. Higgins MJ, Wolff AC (2008) Therapeutic options in the management of metastatic breast cancer. Oncology 22:614-623
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
3. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284
4. Morrison BJ, Schmidt CW, Lakhani SR et al (2008) Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10:210
5. Hortobagyi GN, Spanos W, Montague ED et al (1983) Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 9:643-650
6. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 365:411-422
7. Liu PY, Chen LB, Huang X (2009) The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm 24:91-98
8. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
9. Lu ZH, Jia J, Di LJ et al (2011) DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Front Biosci 1:240-249
10. Yu J, Di LJ, Song GH et al (2011) Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer. Beijing Da XueXue Bao 43(1):151-156
11. Berry DA, Ueno NT, Johnson MM et al (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214-3223
12. Berry DA, Ueno NT, Johnson MM et al (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 29(24):3224-3231
13. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405
14. Crump M, Gluck S, Tu D et al (2008) Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26:37-43
15. Biron P, Durand M, Roché H et al (2008) Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 41:555-562
16. Demirer T, Ilhan O, Mandel NM et al (2000) A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 25:697-703
17. Kroger N, Frick M, Gluz O et al (2006) Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 24:3919-3926
18. Lotz JP, Curé H, Janvier M et al (2005) High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41:71-80
19. Nitz UA, Mohrmann S, Fischer J et al (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366:1935-1944
20. Yu J, Ren J, Di LJ et al (2011) Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor. Chin J Cancer Res 23:49-53